Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Panchagnula

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Die Pharmazie|October 31, 2006
Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective studyR Panchagnula, A Kumar Bajpai, S Agrawal, et al.
Drug Development and Industrial Pharmacy|August 4, 2006
High-throughput evaluation of non-swellable controlled release matrix tabletsR Panchagnula, A Gupta, S Kandavilli, et al.
Indian Journal of Pathology & Microbiology|February 14, 2003
Wolman's disease--a case reportR Panchagnula, C Britto, J Vinod, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 11, 1999
The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHOR Panchagnula, K J Kaur, I Singh, et al.
Methods and Findings in Experimental and Clinical Pharmacology|April 11, 2001
Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulationsR Panchagnula, K J Kaur, I Singh, et al.
Methods and Findings in Experimental and Clinical Pharmacology|February 12, 2000
Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulationsR Panchagnula, I Singh, K J Kaur, et al.
Die Pharmazie|February 8, 2007
Stability of insulin under iontophoretic conditionsR Panchagnula, P Bindra, N Kumar, et al.
Die Pharmazie|January 10, 2006
Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug effluxR Panchagnula, T Bansal, M V S Varma, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 30, 1999
Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC methodR Panchagnula, A Sood, N Sharda, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 6, 2001
Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocolR Panchagnula, S Agrawal, K J Kaur, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Die Pharmazie|October 31, 2006
Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective studyR Panchagnula, A Kumar Bajpai, S Agrawal, et al.
Drug Development and Industrial Pharmacy|August 4, 2006
High-throughput evaluation of non-swellable controlled release matrix tabletsR Panchagnula, A Gupta, S Kandavilli, et al.
Indian Journal of Pathology & Microbiology|February 14, 2003
Wolman's disease--a case reportR Panchagnula, C Britto, J Vinod, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 11, 1999
The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHOR Panchagnula, K J Kaur, I Singh, et al.
Methods and Findings in Experimental and Clinical Pharmacology|April 11, 2001
Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulationsR Panchagnula, K J Kaur, I Singh, et al.
Methods and Findings in Experimental and Clinical Pharmacology|February 12, 2000
Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulationsR Panchagnula, I Singh, K J Kaur, et al.
Die Pharmazie|February 8, 2007
Stability of insulin under iontophoretic conditionsR Panchagnula, P Bindra, N Kumar, et al.
Die Pharmazie|January 10, 2006
Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug effluxR Panchagnula, T Bansal, M V S Varma, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 30, 1999
Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC methodR Panchagnula, A Sood, N Sharda, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 6, 2001
Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocolR Panchagnula, S Agrawal, K J Kaur, et al.
Pageof 6